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Congenital hypertrophy of the retinal pigment epithelium and mandibular
osteomata as markers in familial colorectal cancer*
L.M. Hunt', M.H.E. Robinson', C.E. Hugkulstone, B. Clarke., S.A. Vernon',
R.H.S. Gregson', J.D. Hardcastle' & N.C.M. Armitage'
Departments of'Surgery and 2Ophthalmologv, University ofNottingham, Queen's Medical Centre, Nottingham NG7 2UH, UK.
S_mmary Congenital hypertrophy of the retinal pigment epithelium (CHRPE) and multiple mandibular
osteomata are markers of familial adenomatous polyposis (FAP). We have assessed their prevalence in
non-polyposis familial colorectal neoplasia. Multiple mandibular osteomata were present in 1 29 (3%) patients
with familial colorectal neoplasia. CHRPE was present in 11 33 (33%) patients with familial colorectal
neoplasia compared with 3 36 (8%) with sporadic disease (P = 0.01) and 4 32 (12.5%) control subjects
(P = 0.04). Seven patients with familial colorectal neoplasia had multiple areas of CHRPE compared with one
with sporadic disease (P = 0.02) and one control subject (P = 0.02). There was no obvious correlation between
calculated familial colorectal cancer risk and the presence of multiple areas of CHRPE. A proportion of
patients with familial colorectal cancer have a marker found in FAP and may therefore have a constitutional
genetic defect, at least in part responsible for their cancer, making them an interesting group for genetic study.
Ophthalmoscopy may contribute to risk assessment in familial colorectal cancer.
Individuals carrying the gene for familial adenomatous
polyposis (FAP) can be identified by indirect ophthalmo-
scopy. Multiple areas of retinal hyper- and hypopigmen-
tation, known as congenital hypertrophy of the retinal
pigment epithelium (CHRPE), have been documented in
67-100% of affected patients with FAP. (Traboulsi et al..
1987; Berk et al., 1988; Chapman et al., 1989; Burn et al..
1991; Giardiello et al., 1991; Morton et al., 1992). Not
infrequently, normal individuals have one or two areas of
CHRPE (Chapman et al., 1989; Burn et al., 1991), and
therefore it is thought to be the presence of multiple areas
which is of significance. The gene for FAP has been localised
to 5q21 (Bodmer et al., 1987), and a variety of polymorphic
DNA markers are available (Nakamura et al., 1988; Meera
Khan et al., 1988; Dunlop et al., 1990, 1991), raising the
possibility of exclusion of the carrier status in family
members without the need for annual bowel examination
(Dunlop et al., 1991). Information from eye examination,
bowel examination and DNA analysis may be combined to
calculate revised risk estimates that an individual from an
affected family has inherited the FAP gene.
Multiple mandibular osteomata have been found in 70%
and 76% of FAP patients (Bilow et al., 1984; Giardiello et
al., 1991). It has been suggested that a combination of the
two markers may give useful additional information (Giar-
diello et al., 1991). Unlike the adenomas in FAP, which tend
to occur around puberty, these extracolonic lesions are pre-
sent at birth or shortly afterwards, and can be detected by
means of simple, cheap and relatively non-invasive examina-
tions.
To date there has been little work assessing the incidence
of CHRPE and multiple mandibular osteomata in patients
with familial but non-polyposis colorectal cancer. Traboulsi
et al. (1988) examined six such individuals and found no
areas of CHRPE. In a small study Stephenson et al. (1992)
found three out of eight (37.5%) patients with familial colo-
rectal cancer to have multiple areas of CHRPE, and Houl-
ston et al. (1992) found multiple areas of CHRPE in 3/21
patients who hade adenomas associated with the cancer
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family syndrome. Morton et al. (1992) found CHRPE in five
of ten individuals who were members of five hereditary non-
polyposis colorectal cancer families, however none of these
individuals met the authors' criteria for a positive test.
Sondergaard et al. (1985) identified multiple mandibular
osteomata in 8 of 31 (26%) individuals with familial colorec-
tal cancer, however these individuals were all members of
two large families.
The aim of this study was to assess the incidence of
CHRPE and mandibular osteomata in patients with familial
colorectal neoplasia and to compare this with the incidence
in patients with sporadic colorectal neoplasia and a control
population of unaffected individuals.
Patients and methods
Recruitment
Three groups of patients were recruited (Table I).
Group I (familial colorectal neoplasia, n = 34) Forty-eight
patients under follow-up by the Department of Surgery,
University of Nottingham, were identified as having a first-
degree family history of colorectal cancer. They were con-
tacted by letter and asked if they would participate in the
study. Thirty-four patients agreed to do so. All these patients
were under review in the colorectal cancer clinic, however on
subsequent review of their histology two were found to have
had large adenomas (one 3 cm villous adenoma and one 2 cm
adenoma with severe dysplasia). Thirty-three patients also
had a first-degree family history of colorectal cancer. On
verification of the relatives' diagnoses, one individual's
relative was found to have a 3 cm rectal adenoma, not a
cancer. All 34 patients in the study were from different
families and none was from an FAP family or had evidence
of FAP.
Group 2 (sporadic colorectal neoplasia, n = 36) Patients in
the sporadic colorectal neoplasia group were recruited from
the same colorectal cancer clinic in the Department of
Surgery. Thirty-four patients had colorectal cancer and one
patient a 2 cm adenoma with severe dysplasia. None of these
patients had any relatives with colorectal cancer.
Group 3 control subjects (n = 32) A mixture of spouse con-
trols and surgical patients with no evidence of intestinal
disease were recruited. These individuals were not investi-
gated to exclude colorectal neoplasia. There were more men
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Table I Details of patients
Group I Group 2 Group 3
(familial) (n = 33) (sporadic) (n = 36) (control) (n = 32)
Age (years) 51-79 39-88 24-76
Median (years) 64 74 66
Male 24 21 16
Female 10 15 16
Neoplasm 32 CRC, 35 CRC, Nil
(Patient) two adenoma one adenoma
Neoplasm 33 CRC, Nil Nil
(Relative) one adenoma
CRC, colorectal cancer.
than women in groups 1 and 2, but neither CHRPE nor
mandibular osteomata has been shown to be sex related
(Bilow et al., 1984; Chapman et al., 1989; Burn et al.,
1991).
Method
All individuals had detailed family pedigrees recorded by two
of the authors (L.M.H. and M.H.E.R.), to include at least all
first- and second-degree relatives. Reports of relatives with
colorectal cancer were confirmed by hospital notes, patho-
logy records or death certificates, and in the case of one
patient seen privately a letter from the consultant caring for
the patient. After informed consent, indirt ophthalmoscopy
was carried out by one of two ophthalmologists (C.E.H. and
B.C.) within a specially formed clinic. Pupils were dilated
with tropicamide 1% (w/v) (Smith & Nephew Pharma-
ceuticals, Romford, UK). All hypo- and hyperpigmented
lesions were counted as positive regardless of size (Chapman
et al., 1989; Burn et al., 1991). The presence ofthree or more
lesions was classified as multiple CHRPE. Orthopantomo-
graphy was performed in 29, 29 and 24 individuals in the
familial, sporadic and control groups respectively. The oph-
thalmologists and radiologist were unaware of the group to
which the individual belonged.
Results
Multiple mandibular osteomata
Results oforthopantomography are shown in Table II. Seven
mandibular osteomata were found in five individuals. One
individual with familial colorectal cancer had three
osteomata (3%). There was no significant difference in the
number of osteomata between the three groups. The indivi-
dual with three osteomata did not have any areas of
CHRPE.
Congenital hypertrophy ofthe retinalpigment epitheliun
The results of ophthalmoscopy are shown in Figure 1.
Significantly more patients (11/33) with familial colorectal
cancer were found to have areas of CHRPE compared with
those with sporadic disease (3/36) (Fisher's exact test,
P = 0.01) and control subjects (4/32) (Fisher's exact test,
P = 0.04). However, many normal individuals have one or
Table H Results of orthopantomography
Group 1 Group 2 Group 3
No. of (familial) (sporadic) (controls)
osteomata (n = 29) (n = 29) (n = 24)
None 27 27 23
1 1 2 1
3 1 0 0
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Fugwe 1 Incidence of CHRPE in familal and sporadic colorec-
tal neoplasia and control subjects. 'A patient with colorectal
cancer, and father with colorectal cancer aged 42 years, who had
two areas of CHRPE in the right eye and extensive RPE change
in the left eye was excluded from analysis because of previous
trauma to the left eye.
two lesions, and it is the presence of multiple areas of
CHRPE which is of significance. The precise level of the
upper limit of normal for areas of CHRPE is somewhat
arbitrary, but it has been suggested that three, four or more
areas of CHRPE may he taken to be significant (Chapman et
al., 1989; Burn et al., 1991). One control subject in our series
had five areas of CHRPE. One individual in the sporadic
group had four areas of CHRPE. Seven individuals with
familial colorectal neoplasia had three or more areas of
CHRPE, significantly more than both the sporadic group
(Fisher's exact test, P = 0.02) and the control group (Fisher's
exact test, P = 0.02). Ifwe raise the 'upper limit ofnormal' in
view of our finding of five areas of CHRPE in one of our
control subjects, six remaining patients with familial colorec-
tal neoplasia had multiple areas ofCHRPE [versus the spor-
adic group P = 0.01 (Fisher's exact test) and versus the
control group P = 0.01 (Fisher's exact test)].
If patients with adenomas and/or a relative with an
adenoma are excluded from analysis and only those with
colorectal cancer and a first-degree family history ofcolorec-
tal cancer are analysed, the results are as follows. Six of 33 of
those with familial colorectal cancer had multiple areas of
CHRPE compared with 0 of 36 with sporadic disease
(Fisher's exact test, P= 0.01) and 1 of 32 control subjects
(Fisher's exact test, P = 0.05).
We correlated the presence of multiple areas of CHRPE
with the 'strength of family history' in terms of the number
of affected relatives and the age at which they developed
colorectal cancer (Table Ill). It is interesting to note that the
presence of multiple areas of CHRPE is not confined to
those who have a specific genetic syndrome, but occurs in
those who might before their diagnosis have been deemed to
be at only intermediate cancer risk (Slack, 1989; Houlston et
al., 1990).
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Table m Presec of multiple areas of CHRPE in patients with
diffeing familal risks
Multiple
No. affected relatives n CHRPEs
Dominant pedigree 6 2 (50%)
2 8 0
1 <45 years 3 1 (33%)
1 >45 years 16 4 (27%)
Multiple = three lsions or more.
Dbaion
Unlike results seen in FAP only one individuaL, in our study,
with familial colorectal cancer had multiple mandibular
osteomata (3%), a proportion which would be expected in
the general population (Sondergaard et al., 1985). There was
no statisticaly significant difference in the incidence of mul-
tiple mandibular osteomata between those with familial colo-
rectal cancer and those with sporadic diseas and control
subjects. We would therefore suggest that this investigation is
of no value in the management of familial non-polyposis
colorectal cancer.
The finding of multiple areas of CHRPE in a considerable
proportion (21%) of those with familial colorectal cancer is
of great interest and has potential clinical use. Areas of
CHRPE are benign and typically multiple in affected indivi-
duals. The multiplicity of the lesions and the fact that they
are usually assocated with diffuse diurbances in the retinal
pigment epithelium suggests widespread expression of the
abnormal gene within the retinal pigment epithelial cells.
Multiple areas of CHRPE have been shown to be a very
accurate predictor of carriage of the FAP gene. Work from
the Northern Region Polyposis Registry suggested a cut-off
of two areas of hypertrophy as the upper limit of normal.
This gave a false-positive rate of0% and a false-negative rate
of 7.5% ofcarrying the FAP gene (Chapman et al., 1989). In
subsequent work from the same department (Burn et al.,
1991) one individual (of 92) in the control group (hospital
staff) was found to have three lesions, the presence offour or
more lesions giving a sensitivity of 87.8% and a speificity of
100% for the FAP gene in 48 unrelated pedigrees. It was
therefore concluded by Burn et al. that four or more areas of
CHRPE is diagnostic of FAP. We have now found the same
lesion in individuals with familial non-polyposis colorectal
neoplasia.
In Britain, up to a quarter of all colorectal cancers are
familial (Lovett, 1976; Duncan & Kyle, 1982; Stephenson et
al., 1992). In the nuclear family it is difficult to know whether
a cluster of cancers is of genetic origin or the result of the
shared family environment (Lynch et al., 1985). However the
finding of multiple areas of CHRPE, a lesion which appears
to be independent of environmental factors, in a quarter of
those with familial colorectal neoplasia suggests a constitu-
tional genetic defect in these patients.
Our finding that multiple areas of CHRPE was not con-
fined to those at high familial colorectal cancer risk may
serve to hilight inevitable deficiencies in current methods of
risk estimation. These are necessariy caluated solely on the
basis of the number and ages of affected relatives. In a small
family someone from a dominant pedigree may only have
one first-degree relative with the disease, the small famly size
obscuring the degree of risk to which the individual is sub-
ject. In the future, and in conjunction with other screening
modalities, assent for areas of CHRPE may add to our
ability to esimate risk, therefore facilitating patient and
family ianagement. Although the absence of areas of
CHRPE does not relieve clinicians of their responsibilities to
screen high-risk individuals endoscopically, their presence in
inte miate-ris individuals may identify a group who war-
rant more thorough examination. Although developments in
molecular genetic will probably surpass these simple
methods of risk estimation in years to come, it may be many
years before this is viable. Recently hereditary non-polyposis
colorectal cancer was linked to a gene on chromosome 2 in
two famlies. inage was disproved in a third family (Pe
tomaki et al., 1993). Even as the genes responsible for the
various types of familial colorectal cancer are defined,
inevitably, at kast for the foreseeable future, only a propor-
tion of familes will benefit from such developments.
Examination for areas of CHRPE may add to assessment of
nsk in a similar manner as is currently being used in FAP,
examination of the eyes being simple, cheap and relatively
non-mvasive.
In addition to any possible practical applications, the
identification of multiple areas of CHRPE has defined a
subgroup of those patients with familial colorectal cancer
who have an easily demonstrated marker. What this marker
means in genetic terms is as yet unknown. It would seem
more than coincidence that this is the same marker found in
FAP, and it is reasonable to suppose that these individuals
may have a constitutional genetic defect which is, at least in
part, responsible for their cancer. It is of interest that this
marker has been found not only in those from dominant
pedigrees, but also in those who might previously have been
thought to be at only intermediate risk ofdeveloping colorec-
tal cancer. Undoubtedly this subgroup warrants further
detailed genetic investigation.
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